טוען...
GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
The discoveries of the incretin hormone glucagon-like peptide-1 (GLP-1) and the β-cell hormone amylin have translated into hormone-based therapies for diabetes. Both classes of molecules also exhibit weight-lowering effects and have been investigated for their anti-obesity potential. In the present...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Blackwell Publishing Ltd
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3415643/ https://ncbi.nlm.nih.gov/pubmed/21671898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01537.x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|